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Abstract. Toll-like receptors (TLRs) as well as the
receptors for tumor necrosis factor (TNF-R) and
interleukin-1 (IL-1R) play an important role in innate
immunity by regulating the activity of distinct tran-
scription factors such as nuclear factor-kB (NF-kB).
TLR, IL-1R and TNF-R signaling to NF-kB converge
on a common IkBkinase complex that phosphorylates
the NF-kB inhibitory protein IkBa. However, up-
stream signaling components are in large part recep-
tor-specific. Nevertheless, the principles of signaling
are similar, involving the recruitment of specific
adaptor proteins and the activation of kinase cascades
inwhich protein-protein interactions are controlled by
poly-ubiquitination. In this review, we will discuss our
current knowledge of NF-kB signaling in response to
TLR-4, TNF-R and IL-1R stimulation, with a special
focus on the similarities and dissimilarities among
these pathways.
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NF-kB, does it still need to be introduced?
Nuclear factor kB (NF-kB) is the generic name of a
family of transcription factors that regulate the
expression of a large number of genes involved in
immune and inflammatory responses, as well as in cell
survival, cell proliferation and cell differentiation.NF-
kB transcription factors are activated in response to
various stimuli, including cytokines, infectious agents,
injury and other stressful conditions requiring rapid
reprogramming of gene expression. Inappropriate
activation of the NF-kB signaling pathway is impli-
cated in the pathogenesis of chronic inflammation and
autoimmunity, certain hereditary disorders and vari-
ous cancers. Inmammals, theNF-kB family consists of
five proteins sharing a highly conservedRel homology
domain: c-Rel, RelB, p65 (=RelA), p105 (=NF-kB1)
and p100 (=NF-kB2). The first three contain C-
terminal transactivation domains, while the others
share a long C-terminal domain with multiple copies
of ankyrin repeats, which inhibit their activation.* Corresponding author.
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Partial proteolysis of p105 and p100 results in the
formation of the DNA-binding proteins p50 and p52,
respectively. The highly conserved Rel homology
domain is responsible for DNAbinding, dimerization,
nuclear translocation and interaction with the inhib-
itor of kB (IkB) proteins. All NF-kB family members
are able to form hetero- and homodimers, except for
RelB, which only forms heterodimers. The prototyp-
ical complex corresponds to a heterodimer of p65 and
p50 subunits. NF-kB is kept inactive in the cytoplasm
by members of the IkB family (IkBa, IkBb, IkBg/
p105, IkBd/p100 and IkBe), all containing ankyrin
repeats necessary for binding NF-kB and blocking its
nuclear import. Upon stimulation with for example
tumor necrosis factor (TNF), interleukin-1 (IL-1) or
lipopolysaccharide (LPS), different signaling cascades
are activated, ultimately resulting in activation of an
IkB kinase (IKK) complex, comprising two catalytic
kinase subunits (IKKa and IKKb) and a regulatory
protein [IKKg/NEMO (NF-kB essential modulator)/
IKKAP1 (IKK associated protein 1)/FIP3 (type 2
adenovirus E3–14.7-kD interacting protein)]. Each
kinase contains in its N-terminus the catalytic domain
and in its C-terminus a helix-loop-helix, a leucine
zipper structure and theNEMObinding domain [1, 2].
IKKg contains several structural domains: in its N-
terminal half a first coiled-coil motif responsible for
interaction with IKK kinases [3, 4], and in its C-
terminal half a second coiled-coil motif, a leucine
zipper and a zinc finger motif involved in oligomeri-
zation and interaction with upstream signaling mole-
cules [5, 6]. In addition, IKKg contains a ubiquitin
binding domain between its second coiled-coil motif
and its leucine zipper, shown to bind K63-linked poly-
ubiquitin chains [7, 8]. Activation of the IKK-complex
results in phosphorylation of IkBa at two specific
serine residues (Ser32 and Ser36) by IKKb [9,10],
followed by poly-ubiquitination and subsequent deg-
radation of IkBa by the 26S proteasome. Thereby,NF-
kB is set free and translocates to the nucleus where it
can bind the promoters of genes containing specific
NF-kB-binding sequences. IkBa poly-ubiquitination
on Lys21/Lys22 is mediated by Ubc4/5 ubiquitin
conjugating enzyme (E2), together with the E3-
ubiquitin-protein ligase SCF-bTrCP [Skp1-Cul1-F-
box ligase containing the F-box protein b-transducin
repeat-containing protein (bTrCP)]. bTrCP consists of
bTrCP1 and bTrCP2, specifically recognizing phos-
phorylated IkBa, while the SCF complex contains the
RING domain protein Roc1/Rbx1 and binds Ubc4/5.
Subsequently, Ubc4/5 poly-ubiquitinates IkBa at the
two conserved lysine residues [11]. A fourth protein
that has been isolated as part of the IKK complex is
ELKS, a protein rich in glutamate, leucine, lysine and
serine. ELKS has been implicated as an essential
scaffolding component in the activation of NF-kB in
response to TNF and IL-1, where it would play a role
in the recruitment of IkBa to the IKK complex [12].
Nonetheless, the role of ELKS in IKK and NF-kB
activation needs to be further confirmed through
generation of a knockout mouse strain.
NF-kB activation as described above is referred to as
the canonical or classical NF-kB pathway, which is
activated by different receptors, including TLRs,
TNF-R and IL-1R. Some other receptors such as the
lymphotoxin-b receptor can activate an alternative
NF-kB signaling pathway that results in the phosphor-
ylation of p100 instead of IkBa [1, 2]. We will only
focus on the canonical pathway in this review, as much
more data dealing with the roles of post-translational
modifications targeting the signaling molecules in-
volved in that pathway have been recently generated.
Moreover, the role of the alternative pathway in the
cascades triggered upon stimulation by TLR ligands
or pro-inflammatory cytokines is not so clearly
established.
IL-1R and TLR-4 signaling to NF-kB
The TLR/IL-1R superfamily groups multiple recep-
tors, which all play a crucial role in innate and adaptive
immunity [13]. The TLR subfamily consists of 13
members that contain leucine-rich repeat motifs in
their extracellular domain, which recognize distinct
microbial patterns such as LPS, flagellin, viral double-
stranded RNA and unmethylated CpG motifs. Mem-
bers of the IL-1R subfamily are characterized by
Ig(immunoglobulin)-like structures in their extracel-
lular domain that bind specific IL-1 related cytokines,
which are involved in multiple immunological and
inflammatory processes. In contrast to their distinct
extracellular domains, all members of the TLR/IL-1R
family are characterized by an intracellular TIR
domain. Here we will focus on IL-1RI (the receptor
for IL-1) and TLR-4 (which recognizes LPS in
cooperation with circulating LPS-binding protein,
the co-receptor CD14 [14] and MD-2 [15]) as proto-
types for each subfamily.
Upon binding of IL-1, the IL-1RI associates with IL-1
receptor accessory protein (IL-1RAcP), forming a
functional signaling receptor complex (Fig. 1) [16, 17].
Secondly, the TIR domain containing adaptor protein
MyD88 is recruited to the receptor complex [18]. This
leads to the translocation of the serine/threonine
kinase IL-1 receptor-associated kinase 1 (IRAK-1),
together with the adaptor protein Tollip, into the IL-
1RI complex [18–20]. IRAK-1 is a multidomain
protein containing an N-terminal death domain (DD)
that interacts with theDDofMyD88 [21], followed by
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a domain rich in proline, serine and threonine residues
(ProST region), a serine/threonine-specific protein
kinase domain and a C-terminal domain containing
three TNF receptor-associated factor 6 (TRAF6)
interaction consensus motifs [22–24]. TRAF6 is a
member of a larger TRAF family, containing an N-
terminalRINGdomain, five zinc finger structures and
a conserved C-terminal TRAF domain. The TRAF
domain is responsible for TRAF6 oligomerization,
whereas the RING domain has E3 ubiquitin ligase
activity (see also below). Both TRAF6 as well as the
IRAK-1 related kinase IRAK-4 are recruited at the
activated receptor complex in order to form complex I
[21, 25–27]. IRAK-4 becomes activated by intra-
molecular autophosphorylation of three residues
(Thr342, Thr345 and Ser346) within its activation
loop, which is required for optimal kinase activity of
IRAK-4 [28]. Activation of IRAK-4 leads to phos-
phorylation of IRAK-1 on Thr209 and Thr387 in its
activation loop, leading to full kinase activity [23, 29].
Subsequently, IRAK-1 becomes hyperphosphorylat-
ed in its ProST region, probably via autophosphor-
ylation, resulting in its dissociation from MyD88 and
Tollip, but not from the downstream signaling mole-
cule TRAF6 [21, 23]. However, the kinase activity of
IRAK-1 is dispensable for IL-1 signaling towards NF-
kB, as complementation of cells deficient in IRAK-1
with a kinase death mutant can restore IL-1-induced
NF-kB activation [29]. In contrast, contradictory data
are published about the necessity of the kinase activity
of IRAK-4. In human IRAK-4-deficient cells, resto-
ration of IL-1-mediated NF-kB activation can be
achieved with a kinase inactive mutant [25], while this
was not the case for murine embryonic fibroblasts
derived from IRAK-4 knockout mice [26]. Further-
more, Qin et al. demonstrated that only impairment of
the kinase activity of both IRAK-1 and IRAK-4
abolishes IL-1 signaling, suggesting redundancy of
both kinase activities [25]. These contradictory out-
comes might reflect cell type- or species-specific
differences.
After dissociation from the receptor complex, the
IRAK-1-TRAF6 complex interacts with a pre-exist-
ing TAK1 (transforming growth factor b-activated
kinase 1)-TAB1 (TAK1-binding protein)-TAB2 (or
TAB3) membrane-bound complex, thus forming
complex II [27]. The TRAF6-TAK1-TAB1-TAB2/3
complex then translocates to the cytosol, whereas
IRAK-1 stays at the membrane and becomes poly-
ubiquitinated [27, 29 –31]. The precise function of
IRAK-1 poly-ubiquitination is still unclear. Two types
of poly-ubiquitination have been described, depend-
ing on the specific ubiquitin lysine residue that is used
for making the inter-ubiquitin linkage. K48-linked
poly-ubiquitination triggers proteasome-dependent
degradation, whereas K63-linked poly-ubiquitination
does not trigger degradation of the modified protein
but forms a recognition signal for the binding of other
proteins [11]. IL-1 has been shown to trigger IRAK-1
degradation by the proteasome, which is indicative of
K48-poly-ubiquitination [29–31]. However, Cohen
and colleagues recently demonstrated that IL-1 trig-
gers K63-poly-ubiquitination of IRAK1 (which helps
its binding to NEMO) instead of K48-poly-ubiquiti-
nation [32]. Moreover, they showed that the IL-1-
mediated degradation of IRAK-1 does not occur
through the proteasome, which is in agreement with
Ordureau et al. who claimed that the proteasome
inhibitor MG-132 had no effect on the IL-1-induced
disappearance of IRAK-1 [32, 33]. The identification
of the specific ubiquitin ligases for IRAK-1 might
further clarify the function of different types of IRAK-
1 poly-ubiquitination. In this context, different mem-
bers of the Pellino family were shown to K63-poly-
ubiquitinate IRAK-1 using a novel CHC2CHC2
RING motif, thereby functioning as an E3 ubiquitin
ligase for IRAK-1 [33–36]. Furthermore, binding of
Pellino proteins with IRAK-1 and IRAK-4 depends
on IRAK kinase activity and is associated with
phosphorylation of Pellino [33, 34, 37], which has
been shown to enhance E3 ligase activity as well as
degradative poly-ubiquitination of Pellino [33, 35].
Clearly, the exact function of IRAK-1 and Pellino
poly-ubiquitination needs more investigation.
In the cytoplasm, TRAF6 interacts with the E2
ubiquitin-conjugating enzyme complex Ubc13/
Uev1A, thus forming complex III. Ubc13/Uev1A co-
operates with the RING finger domain of TRAF6,
which acts as an E3-ubiquitin ligase, and results in
K63-linked poly-ubiquitination of TRAF6, which is
necessary for IKK and c-jun N-terminal kinase (JNK)
activation [22, 38, 39]. The RING finger domain of
TRAF6 is necessary for Ubc13 interaction and self-
association [40]. The crucial role of TRAF6 in NF-kB
signaling is demonstrated by the fact that cells isolated
from TRAF6-deficient mice fail to activate NF-kB in
response to IL-1 or LPS [41, 42]. Ubc13 is also
required for TRAF6 poly-ubiquitination and IKK
activation in vivo, as spleen lysates from LPS-treated
mice heterozygous for Ubc13 show lower poly-ubiq-
uitination of TRAF6 than isolates from wild-type
mice. IkBa degradation in response to LPS is also
impaired in macrophages and splenocytes from
Ubc13+/– mice [43]. In contrast, Yamamoto et al.
revealed that Ubc13-deficient murine embryonic
fibroblasts show normal activation of NF-kB in
response to IL-1, whereas JNK activation is impaired
[44]. Furthermore, TRAF6 poly-ubiquitination and
TAK1 activation are normal in Ubc13-deficient cells;
however, IKKg poly-ubiquitination upon IL-1 stim-
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Figure 1. IL-1 signaling pathways to NF-kB. (A) TAK1-dependent pathway. Upon receptor triggering with IL-1, IL-1RI forms a complex
with IL-R1AcP, leading to recruitment ofMyD88,Tollip, IRAK-1, IRAK-4andTRAF6 to formcomplex I. Formationof complex I triggers
IRAK-4 autophosphorylation and the phosphorylation of IRAK-1. Subsequently, IRAK-1 leaves the receptor complex together with
TRAF6 and associates with the pre-formedTAK1-TAB1-TAB2/TAB3 complex at themembrane (complex II).Here IRAK-1 isK63-poly-
ubiquitinated by Pellino, which is itself phosphorylated by IRAK-1. Subsequently, IRAK-1 most likely becomes K48-poly-ubiquitinated
and degraded. Likewise, phosphorylation of Pellino by IRAK-1 leads to K48-poly-ubiquitination and degradation of Pellino. Then,
TRAF6-TAK1-TAB1-TAB2/TAB3 leaves the membrane (complex III). In the cytoplasm, TRAF6 associates with the E2 ubiquitin-
conjugating enzyme (Ubc13/Uev1A) and undergoes auto-ubiquitination with K63-linked poly-ubiquitin chains. This triggers the binding
of TAB2 and activation of TAK1, which subsequently phosphorylates IKKb. IKKb phosphorylates IkBa, leading to its K48-linked poly-
ubiquitination by SCF-bTrCP and proteasome-dependent degradation. In this way, NF-kB (shown as p65/p50 dimers) is set free and
translocates to the nucleus to bind the promoters of responsive genes. (B) TAK-1-independent/PKC-dependent pathway. Upon IL-1
stimulation, TRAF6 can also interact with p62, leading to activation of atypical PKCs and phosphorylation of IKKb. (C) TAK-1-
independent/MEKK-3-dependent pathway. Upon IL-1 stimulation, IRAK-1 and TRAF6 can also interact with MEKK-3, leading to
activation of IKKa, which subsequently phosphorylates IkBa in a way that does not trigger its recognition by SCF-bTrCP and proteasome-
dependent degradation. Phosphorylated IkBa dissociates from NF-kB, thus allowing NF-kB to translocate to the nucleus.
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ulation is impaired [44]. As UbcH7 is also known to
mediate K63-linked poly-ubiquitination of TRAF6
[45], there might be redundancy for TRAF6 auto-
ubiquitination, but not for IKKg poly-ubiquitination
by TRAF6. Furthermore, RNA interference-mediat-
ed knock-down of either Ubc13 or Uev1A abolishes
TRAF6-induced NF-kB activation, IKKg poly-ubiq-
uitination and p65 nuclear translocation upon LPS
stimulation [46]. Finally, TAB2, TAB3 and IKKg also
become K63-poly-ubiquitinated by TRAF6 [22, 47–
49]. A role for oligomerization of TRAF6 in enhanc-
ing its ubiquitinating activity has also been postulated
[39,42,43]. In fact, TRAF-interacting protein with a
forkhead-associated domain (TIFA) was found to
interact with TRAF6, thereby inducing TRAF6
oligomerization and enhancing TRAF6 ubiquitinat-
ing activity [50]. Endogenous TIFA constitutively
associates with TRAF6, whereas it only interacts with
IRAK-1 upon IL-1 stimulation [51]. In addition,
overexpression of TIFA induces NF-kB and JNK
activation in HEK293 cells [52]. Lysine 124 in TRAF6
was identified as the main ubiquitin acceptor site for
auto-ubiquitination, and mutation of this lysine leads
to impaired TAK1, IKK and JNK activation [22].
Moreover, complementation of TRAF6-deficient
cells with this mutant or a RING finger mutant does
not restore TRAF6 auto-ubiquitination, IKKg poly-
ubiquitination, and subsequent IKK activation upon
IL-1 stimulation [22], demonstrating an essential role
for TRAF6E3 ligase activity in signaling. To conclude,
oligomerization of TRAF6 might lead to auto-poly-
ubiquitination of TRAF6, which is necessary for IL-1-
and LPS-inducedNF-kB activation, whereas TRAF6-
induced poly-ubiquitination of NEMO might rather
play a role in IL-1-induced JNK activation.
TAB1, TAB2 and TAB3 have been described as
adaptors for TAK1 [48, 53]. However, the role of
TAB1 in IL-1-induced NF-kB activation has been
argued. In TAB1 knockout cells, no effect on IL-1-
induced NF-kB activation could be observed, suggest-
ing that TAB1 is dispensable for this [54]. In contrast,
although RNA interference-mediated knock-down of
TAB1 had no effect on IL-1-induced nuclear local-
ization of p65, the levels of IL-6, IL-8 and GM-CSF
upon IL-1 stimulation of these cells was markedly
reduced [55]. Furthermore, Mendoza et al. could not
observe any IL-1-induced activity of TAK1 in TAB1-
deficient cells [56]. These contradictory results might
be explained by the existence of TAK1-independent
signaling pathways (see further) or possible effects of
TAB1 on p65 transactivation. TAB2 and TAB3
contain two ubiquitin-binding domains that are re-
quired for their NF-kB activating function [49, 57]: an
N-terminal CUE domain and a C-terminal nuclear
protein localization 4 zinc finger (NZF) [49, 53].
Although the CUE domain interacts with ubiquitin in
a yeast two-hybrid system, it is dispensable for TRAF6
binding [57]. TheNZFdomain, in contrast, is involved
in binding to poly-ubiquitin chains of TRAF6 [49].
Therefore, TAB2 and TAB3 are proposed to function
as adaptor proteins linking TRAF6 to TAK1 [48, 58].
However, TAB2–/– murine embryonic fibroblasts ex-
hibit normal IL-1-induced NF-kB activation [59],
probably due to redundancy with TAB3. Indeed,
RNA intereference-mediated knockdown of both
TAB2 and TAB3 abrogates IL-1-induced NF-kB and
JNK activation [48]. In contrast, Kishida et al.
demonstrated that IL-1-induced TRAF6 poly-ubiq-
uitination and TAK1 auto-phosphorylation are abol-
ished in TAB2-deficientmurine embryonic fibroblasts
[57]. In addition, TAB2 was shown to facilitate the
interaction between TRAF6 and the IKK complex. In
contrast to TAB2 and TAB3, TAB1 does not recog-
nize poly-ubiquitin chains, but is implicated in the
regulation of the kinase activity of TAK1 [60]. TAK1
kinase activity is only detected in complex III [27], and
TAK1 becomes activated upon poly-ubiquitin binding
of TAB2 or TAB3. In fact, TAB2 activates TAK1, and
subsequently the IKK complex, only in the presence
of ubiquitination components, including E1, Ubc13/
Uev1A (E2), TRAF6 (E3) and ubiquitin [39], de-
pending on its NZF domain [49]. Likewise, the NZF
domain of TAB3 is indispensable for TAK1 and IKK
complex activation.Activation of TAK1 leads to auto-
phosphorylation and phosphorylation of TAB1,
whereas TAB2 becomes phosphorylated at the mem-
brane, probably by an upstream protein kinase, as
TAK1 kinase activity is only detected in complex III
[27, 58]. Finally, activated TAK1 is able to phosphor-
ylate IKKb on serines 177 and 181 in its activation
loop, thus activating the IKK complex [39]. RNA
interference directed against TAK1 abolishes IL-1-
mediated NF-kB activation [61], demonstrating its
important role in IL-1-induced activation of the NF-
kB pathway. In addition, murine embryonic fibro-
blasts expressing an inactive form of TAK1 are
impaired in IL-1-mediated NF-kB activation, al-
though IL-1-induced NF-kB activation is not com-
pletely abrogated in these cells [62]. Similarly, B-cells
expressing this TAK1 mutant show impaired IkBa
degradation and NF-kB DNA binding in response to
LPS. Shim et al. revealed that TAK1-deficient murine
embryonic fibroblasts are defective in IL-1-induced
NF-kB activation, but LPS-mediated NF-kB activa-
tion is only partially reduced in these cells [54]. This
partial reduction in signaling in TAK1-deficient cells
upon IL-1 andLPS triggering suggests the existence of
yet to be fully characterized TAK1-independent
pathways.
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One good candidate could be mitogen-activated
protein kinase kinase kinase 3 (MEKK3), as
MEKK3-deficient cells show impaired NF-kB activa-
tion upon IL-1 signaling. In addition, IL-1-induced
IkBa phosphorylation is only completely abolished
when both TAK1 and MEKK3 are impaired [63]. In
this context, Yao et al. proposed the existence of two
independent signaling pathways to NF-kB upon IL-1
stimulation. The TAK1-dependent pathway leads to
IKKb phosphorylation and activation through the
classical pathway, resulting in IkBa phosphorylation
and degradation. The TAK1-independent, MEKK3-
dependent pathway involves IKKg phosphorylation
and IKKa activation. Remarkably, the latter results in
NF-kB activation through IkBa phosphorylation and
dissociation from NF-kB, but is not associated with
IkBa degradation [63]. Indeed, IL-1-induced IKKa
and IKKb phosphorylation was shown to be reduced
in TAK1-deficient cells, whereas IKK kinase activity
was intact. In addition, IKKg was phosphorylated
upon IL-1 stimulation of these cells. TAK1 inhibition
abolishes IL-1-induced IkBa phosphorylation in
IKKa-deficient cells, but not in IKKb-deficient cells.
In the TAK1-independent pathway, IkBa phosphory-
lation by IKKa is not recognized by bTrCPE3 ligase, so
no IkBa degradation occurs. Still, NF-kB is dissociated
and translocates to the nucleus. Interestingly, Solt et al.
also demonstrated the existence of an IKKa/IKKg-
dependent, but IKKb-independent, IL-1-mediated sig-
naling pathway to NF-kB [64]. Furthermore, MEKK3
interacts with IRAK-1 and TRAF6 upon IL-1 stim-
ulation. The existence of this alternative pathway could
be demonstrated in primary colon epithelial cells upon
IL-1 and LPS stimulation [63].
Protein kinase C (PKC) is also a likely candidate for
substituting TAK1. Indeed, depletion of atypical
PKCs or p62, an atypical PKC-interacting protein,
inhibits NF-kB, but not JNK activation in response to
IL-1 or TRAF6 overexpression [65]. In addition,
TRAF6 specifically interacts with p62 upon IL-1
stimulation. The fact that p62 noncovalently interacts
with mono- and poly-ubiquitin in a yeast two-hybrid
system [66] suggests that p62 binds ubiquitinated
TRAF6.
Finally, ECSIT (evolutionarily conserved signaling
intermediate in Toll pathways) is another TRAF6-
interacting protein that was shown to be involved in
LPS- and IL-1-induced signaling [67]. Overexpression
of a dominant-negative mutant or RNA interference-
mediated knock-down of ECSITexpression abolishes
LPS- and IL-1-mediated NF-kB activation. The exact
function of ECSIT, is however, still unclear.
Although TLR-4 and IL-1RI have a related intra-
cellular TIR domain that initiates downstream signal-
ing, TLR-4 adds a little variation to the general theme
(Fig. 2). In contrast to the IL-1RI complex, recruit-
ment of MyD88 to TLR-4 is dependent upon TIR-
domain-containing adaptor protein (TIRAP), also
known as MyD88 adaptor like (Mal). Indeed, Mal-
deficientmice do not produce inflammatory cytokines
in response to LPS [68, 69]. Recently, it was shown
that Mal contains a phosphatidylinositol 4,5-bisphos-
phate (PIP2)-binding domain, targeting Mal to dis-
crete regions in the plasmamembrane. MyD88 is then
recruited to the plasma membrane to interact with
Mal via their TIR domains. Mutations of the PIP2-
binding domain result in an impairment of Mal and
subsequent MyD88 recruitment to the plasma mem-
brane. As bypassing Mal requirement by endowing
MyD88 with a PIP2-binding domain restores TLR-4
signaling in Mal-deficient cells [70], it has been
suggested that Mal only functions to recruit MyD88
to the PIP2-containing membrane part. Such a bridg-
ing function for Mal was also demonstrated using
MAPPIT, a mammalian two-hybrid system [71].
Furthermore, upon LPS stimulation, Mal becomes
tyrosine phosphorylated by Brutons tyrosine kinase
(Btk) [72]. Tyrosine phosphorylation of Mal is neces-
sary for NF-kB activation by LPS, but the mechanism
remains unknown. Possibly, tyrosine phosphorylation
of Mal induces conformational changes that unmask
the PIP2-binding domain. However, no experimental
evidence for this is available yet.
Secondly, a MyD88-independent signaling pathway
originates from TLR-4. Although MyD88-deficient
cells fail to express several inflammatory cytokines
upon LPS stimulation, LPS still induces a delayed
activation of NF-kB and JNK [73]. Furthermore,
induction of type I interferons (IFNs) is not impaired
[74], pointing to the existence of a second signaling
pathway from TLR-4 upon LPS stimulation. This
MyD88-independent signaling pathway involves the
recruitment of TRIF-related adapter molecule
(TRAM, also known as TICAM2) and TIR domain-
containing adapter-inducing IFNb (TRIF, also known
as TICAM1). Recently, TLR-4 was shown to activate
the MyD88-dependent and TRIF-dependent signal-
ing pathways sequentially in a process organized
around endocytosis of the TLR-4 complex [75].
More specifically, TLR-4 first induces Mal-MyD88
signaling at the plasma membrane and is then
endocytosed and activates TRAM-TRIF signaling
from early endosomes. TRIFassociates with TRAF6
and receptor-interacting protein 1 (RIP1) to induce
NF-kB activation, while activation of the IKK-
related kinases TANK-binding kinase 1 (TBK1)
and IKKe by TRIF results in dimerization and
phosphorylation of the transcription factor IFN
regulatory factor 3 (IRF3), which binds and activates
type I IFNpromoters in the nucleus (for overview see
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[76]). Similar to MyD88-deficient cells, TRAF6-
deficient macrophages also demonstrate a delayed
activation of NF-kB and JNK upon LPS stimulation,
but unaffected IFN production, suggesting that
TRAF6 is essential for MyD88-dependent, but not
TRIF-dependent signaling [77].
Upon LPS stimulation, the scaffolding protein B-cell
leukemia/lymphoma 10 (BCL10) is recruited into the
TLR-4 receptor complex via its interaction with
IRAK-1 [78]. Furthermore, IRAK-1 oligomerization
stimulates BCL10 oligomerization, which is necessary
for LPS-induced NF-kB activation. The BCL10-
interacting protein mucosa-associated lymphoid tis-
Figure 2. LPS signaling pathways to NF-kB. LPS in complex with LPS-binding protein (LBP) binds CD14 on the cell membrane, which
transfers LPS toMD-2 and TLR-4. (A) In contrast to IL-1RI signaling, MyD88 is recruited to the receptor complex via its interaction with
Mal, which is attached to the membrane by its PIP2-binding domain. Complex I, II and III formation proceeds as described in Figure 1 for
IL-1R1 signaling, but in addition, IRAK-1 interacts with BCL10 in complex I. BCL10 binds to Pellino2 in complex II and with MALT1 in
complex III.MALT1 further contributes to TRAF6 activation. (B) Upon LPS stimulation, the adaptor proteins TRAMand TRIFare also
recruited to TLR-4 (TRIF and MyD88 are here shown in the same TLR-4 complex, but recent evidence indicates their sequential
recruitment, with TRAM and TRIF being recruited on endosomal TLR-4). TRIF associates with RIP1 to induce a late-phase NF-kB
activation.To this end, poly-ubiquitinatedRIP1associateswith poly-ubiquitinatedTRAF6and theTAB-TAK1 complex. In additionTRIF
initiates a pathway leading to the activation of TBK1 and IKKe and subsequent IRF3 activation by phosphorylation, a step required for
type I IFN induction.
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sue 1 (MALT1) is also an essential intermediate in the
LPS-signaling cascade towards NF-kB since RNA
interference against MALT1 abolishes LPS-induced
NF-kB activation. Moreover, TRAF6 auto-ubiquiti-
nation is markedly reduced upon LPS stimulation of
MALT1-deficient macrophages [78]. LPS stimulation
effectively induces BCL10-MALT1 and MALT1-
TRAF6 interactions, indicating that the BCL10-
MALT1-TRAF6 signaling cascade to NF-kB is not
only important in T-cell receptor signaling but also in
the TLR-4 pathway. Upon LPS stimulation, MALT1
can only be detected in the cytosolic TAK1 complexes,
whereas BCL10 is also found in TLR-4 and TAK1
complexes at the membrane. In addition, no IRAK-1
can be detected in the cytosolic TAK1 complex,
suggesting that BCL10 dissociates from IRAK-1
before binding to MALT1 in the cytosolic TAK1
complex [78]. Pellino-2 was also found to interact with
BCL10 in both the membrane-bound and cytosolic
TAK1 complex, and its knock-down inhibits the
recruitment of BCL10 to the cytosolic TAK1 complex.
Recently, a role for the cysteine protease caspase-1 in
TLR-4 signaling to NF-kB was described [79]. Cas-
pase-1 binds and cleaves the adaptor protein Mal. In
addition, LPS signaling is impaired in caspase-1-
deficient cells, and a non-cleavable Mal mutant acts
as a dominant-negative inhibitor towards TLR-4
signaling. Finally, also human caspase-4, which does
not have a murine ortholog, has been implicated as an
essential mediator of LPS-induced NF-kB activation
via its interaction with TRAF6 [80]. The underlying
mechanism by which caspase-4 mediates NF-kB
activation is, however, still unclear.
TNF-R signaling to NF-kB
TNF exerts its function by binding, as a trimer, to
either TNF-R1 or TNF-R2. Both TNF receptors
belong to the so-called TNF receptor superfamily,
with several of its members playing a pivotal role in
the development and function of the immune system
[81]. All TNF receptor family members are charac-
terized by the presence of one to six cysteine-rich
domains in their extracellular portion. They can be
further divided based on the presence of specific
signaling motifs or domains in their cytoplasmic tails:
a first subgroup for which TNF-R1 is representative
shares a death domain (DD); a second subgroup,
which includes most TNF-R family members includ-
ing TNF-R2 contains a consensus motif that allows
binding to TRAF signaling proteins; and a third
subgroup does not contain any known signaling
motifs. TNF-R2 expression and biological responses
are mainly restricted to T cells. We will therefore in
this review focus on TNF-R1 as a universal receptor
for TNF.
Similarly as discussed above for the sequential for-
mation of distinct TLR-4 signaling complexes at the
plasmamembrane and endosomal membrane, respec-
tively, TNF-R1 signaling also involves the formation
of two sequential signaling complexes [82–84]. Upon
activation of TNF-R1 at the plasma membrane, the
TNF-R1 DD serves as a docking site for the DD-
containing adaptor protein TRADD through homo-
typic DD interactions. TRADD, in turn, recruits TNF
receptor-associated factor 2 (TRAF2) and the serine/
threonine kinase RIP1 [85, 86], which rapidly signal
NF-kB activation (Fig. 3). At later time points,
TRADD, RIP1 and TRAF2 dissociate from TNF-
R1, and endosomal TNF-R1 recruits the DD-contain-
ing adaptor protein FADD, which binds itself to
caspase-8, forming a cytoplasmic complex that is
implicated in signaling to apoptosis [86]. In addition to
TRAF2, TRAF5 has also been implicated in TNF-
induced NF-kB activation, as in contrast to the single
TRAF2 or TRAF5 knockout cells, TRAF2/TRAF5
double-knockout cells show impaired NF-kB activa-
tion upon TNF stimulation [87, 88]. Unlike TRAF2,
TRAF5 only interacts with RIP1, but not with
TRADD in co-immunoprecipitation assays [87].
TRAF2 becomes K63-linked poly-ubiquitinated
upon TNF stimulation, which is dependent on its
RING and zinc finger domains and which requires
Ubc13/Uev1A. Similarly to TRAF6, TRAF2 has
therefore been proposed to be an E3 ubiquitin ligase
[89, 90]. In vitro, TRAF2 can generate K63-linked
poly-ubiquitin chains via an E2 Ub-conjugating en-
zyme Ubc13/Uev1A-dependent mechanism [38]. The
necessity of the E3 ligase activity of TRAF2 for TNF-
induced NF-kB activation remains controversial, as
TRAF2 translocation and poly-ubiquitination was
demonstrated to be required for JNK, but not NF-kB
activation upon TNF stimulation [89, 90]. However,
the RING finger structure of TRAF2 is necessary for
TNF-induced NF-kB activation [85]. Also, a naturally
occurring splice variant of TRAF2, called TRAF2A,
containing a mutated RING finger domain, is unable
to activate NF-kB but remains a potent activator of
the JNK pathway [91]. The fact that depletion of
TRAF2 is sufficient to abolish TNF-induced JNK
activation, whereas depletion of both TRAF2 and
TRAF5 are necessary for abrogating NF-kB activa-
tion [87], suggests possible redundancy between
TRAF2 and TRAF5 for TNF-induced NF-kB activa-
tion. However, no E3 ligase activity has been demon-
strated yet for TRAF5. Furthermore, an intact RING
finger structure is required for NF-kB activation, but
not for JNK activation, by TRAF5 [91].
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Figure 3. TNF signaling pathways to NF-kB. Upon TNF stimulation, plasma membrane-associated TNF-receptor 1 (TNF-R1) trimerizes
and recruits via its death domain TRADD, which binds itself TRAF2 and RIP1, which also interacts with TRAF5. Upon TNF-R1
endocytosis, TRADD dissociates from TNF-R1 and associates with FADD, leading to recruitment of caspase-8, which initiates pro-
apoptotic signaling. TRAF2 undergoes auto-poly-ubiquitination and ubiquitinates RIP1 via K63-linked poly-ubiquitin chains. (A) RIP1
poly-ubiquitination leads to the recruitment of TAK1 and IKKb via respectively TAB2 and IKKg, which binds to the poly-ubiquitin chain
of RIP1. Finally, TAK1 phosphorylates IKKb, leading to the activation of the IKK complex as described for Figure 1. (B) Upon TNF
stimulation, RIP1 also recruitsMEKK3, which phosphorylates IKKb, leading to activation of the IKK-complex. TAK1 is necessary for the
regulationof the kinase activity ofMEKK3. (C)RIP1 can also interactwith p62, leading to activationof aPKCs and theTAK1-independent
activation of the IKK complex.
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RIP1 and TRAF2 can be recruited to the TNF-R1
complex independent of each other, as RIP1 and
TRAF2 were shown to be recruited to the TNF-RI
complex upon TNF stimulation in TRAF2-deficient
and RIP1-deficient cells, respectively [92, 93]. Upon
TNF stimulation, TNF-R1, together with TRADD,
TRAF2 and RIP1, are relocated to lipid rafts, which
are microdomains in the membrane that are enriched
in sphingolipids and cholesterol [94].Moreover, TNF-
R1 and RIP1 become poly-ubiquitinated in lipid rafts
upon TNF stimulation [93, 94]. RIP1-deficient cells
fail to activate NF-kB upon TNF-stimulation, dem-
onstrating the essential role for RIP1 in TNF signaling
to NF-kB [95]. In addition, RIP1 plays a role in the
recruitment of TAK1, as TAK1 fails to translocate to
the TNF-R1 complex upon TNF stimulation of RIP1-
deficient Jurkat cells [96]. In response to TNF, RIP1
becomes K63-poly-ubiquitinated at lysine 377 in its
intermediate domain. This is indispensable for IKK
activation upon TNF stimulation, as mutation of
lysine 377 abolishes the ability of RIP1 to rescue
IKK activation in RIP1-deficient cells [97, 98].
Although previous reports indicated that TRAF2 is
necessary for recruitment of the IKK complex and
that RIP1 mediates IKK activation [85, 92], RIP1-
deficient cells stably transfected with a RIP1 lysine
377mutant fail to recruit TAK1 and IKKg to the TNF-
R1 upon TNF stimulation [9, 97, 98]. So, poly-
ubiquitination of RIP1 on lysine 377 is not only
necessary to recruit TAK1, via binding to TAB2, but is
also needed to directly recruit IKKg [97]. Binding of
IKKg via itsNEMOubiquitin-binding domain toK63-
poly-ubiquitinated RIP1 [7, 8] is necessary for IKK
activation upon TNF stimulation, as mutations in the
NEMO ubiquitin-binding domain abolish TNF-in-
duced NF-kB activation [8, 97]. As IKKg interacts
with K63-linked poly-ubiquitin chains in vitro [97],
and also binds the intermediate domain of RIP1 [84,
99], IKKg most likely interacts directly with the
ubiquitin chains on RIP1 via its NEMO ubiquitin-
binding domain. In vivo, endogenous IKKg only co-
immunoprecipitated with RIP1 after TNF stimula-
tion, and RIP1 was immunoprecipitated as a ladder of
highermolecularweight bands, which represents poly-
ubiquitinated forms of RIP1 [8]. In addition, binding
of IKKg to poly-ubiquitinatedRIP1 protects the latter
from proteasome-mediated degradation [8], probably
by preventing de-ubiquitination of K63-poly-ubiqui-
tinated RIP1 and subsequent K48-linked ubiquitina-
tion by A20 [100]. Similar to IRAK-1 in the IL-1 and
LPS signaling pathway, the kinase activity of RIP1 is
also dispensable for IKK activation and RIP1 poly-
ubiquitination [93]. TRAF2might be theE3-ligase for
RIP1, as no poly-ubiquitination of RIP1 occurs in
TRAF2-deficient cells upon TNF stimulation [93].
Moreover, overexpression of TRAF2 in HEK293T
cells induces K63-poly-ubiquitination of RIP1 [100].
Ubc13 also plays an essential role inTNF-inducedNF-
kB activation, as macrophages and splenocytes iso-
lated from Ubc13+/– mice stimulated with TNF show
impaired IkBa degradation [43]. Furthermore,
siRNA directed against either Ubc13 or Uev1A
abolishes TRAF2-mediated signaling to NF-kB [46].
In contrast, Yamamoto et al. demonstrated that
Ubc13-deficient murine embryonic fibroblasts show
normal activation of NF-kB and JNK in response to
TNF [44].
The TAK1/TAB1/TAB2/TAB3 complex is also impli-
cated in TNF signaling. As with IL-1 and LPS
signaling, TAB2 and TAB3 are redundant for TNF-
induced NF-kB activation. Indeed, while TAB2-
deficient murine embryonic fibroblasts still exhibit
normal TNF-induced NF-kB activation [59], RNA
interferencemediated knock-down of both TAB2 and
TAB3 abrogates TNF-mediated signaling [48]. Upon
TNF stimulation, poly-ubiquitinated RIP1 associates
with TAB2, but poly-ubiquitinated TRAF2 does not
[49]. In contrast, Ishitani et al. could show an
interaction between TAB2 or TAB3 and TRAF2
upon TNF stimulation [48]. Unlike TRAF6, co-
expression of TRAF2 with TAB2 or TAB3 does not
lead to poly-ubiquitination of TAB2 and TAB3. In
contrast to IL-1 stimulation, however, RNA interfer-
ence-mediated downregulation of TAB1 had no effect
on p65 nuclear localization and expression of IL-6, IL-
8 and GM-CSF, demonstrating a differential role for
TAB1 in IL-1 and TNF signaling pathways [55].
However, stimulation of TAB1-deficient cells with
TNF did not lead to activation of TAK1 [56]. The
essential role of TAK1 in TNF signaling was demon-
strated by the use of RNA interference directed
against TAK1 and the generation of TAK1-deficient
murine embryonic fibroblasts, which both lead to an
impairedNF-kBactivation upon TNF stimulation [49,
54, 62, 96, 97].
Furthermore, an important role for another MAP
kinase kinase kinase, MEKK3, in TNF-induced NF-
kB activation has been revealed by the generation of
MEKK3-deficient murine embryonic fibroblasts,
which are impaired in TNF signaling [101]. MEKK3
can be recruited to the receptor complex upon TNF-
triggering via RIP1 [101, 102]. In addition, MEKK3
associates with and phosphorylates IKKb in vitro
[102]. TAK1 kinase activity was demonstrated to
regulate the kinase activity of MEKK3 [96], but
MEKK3 is not a direct substrate for TAK1 [97]. In
addition, knock-down of TAK1 blocks RIP1-induced
NF-kB activation, but not MEKK3-induced NF-kB
activation, suggesting that TAK1 acts downstream of
RIP1, but upstream of MEKK3. Remarkably, the
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kinase activity of MEKK3 is indispensable for TNF-
mediated NF-kB activation [101]. Moreover, TAK1-
TAB1 overexpression can still activate NF-kB in
MEKK3-deficient cells [96], suggesting that similar to
IL-1 signaling, two independent TNF signaling path-
ways might exist, a TAK-1-dependent and a TAK1-
independent/MEKK3-dependent pathway. In this
regard, Di et al. demonstrated very recently an
important role for TAB1 in MEKK3 and TAK1
signaling upon TNF stimulation [103]. They could
show a physical interaction between MEKK3 and
unphosphorylated TAK1, leading to inhibition of
MEKK3 phosphorylation and NF-kB activation.
However, TAK1 becomes phosphorylated upon co-
expression of TAB1 and dissociates from MEKK3,
leading to activation of NF-kB. These results also
demonstrate the existence of two signaling pathways
upon TNF stimulation, which regulate each others
activation and explain the indirect dependence of
MEKK3 on the kinase activity of TAK1.
Like TRAF6 in the IL-1 signaling pathway, RIP1
interacts with p62 upon TNF stimulation [104]. In
addition, overexpression of dominant-negative forms
of atypical PKCs or knock-down of p62 abolishes
RIP1-induced, but not TRAF2-induced NF-kB acti-
vation, suggesting that p62 might represent an inde-
pendent signaling pathway towards NF-kB activation
upon TNF stimulation.
Conclusions
Signaling in response to TLRs, IL-1RI and TNF-R1
shows an ever-growing complexity of molecules and
networks. Because of their related intracellular TIR
domain, TLR-4 and IL-1R signaling share a common
MyD88-dependent signaling pathway that is involved
in NF-kB activation, but inclusion of an MyD88-
independent pathway has provided unique functions
to TLR-4. Moreover, it is not clear why TLR-4 needs
Mal to recruit MyD88, whereas IL-1RI does not. The
extra recruitment of Mal might not only recruit
MyD88 to the membrane but also provide an addi-
tional platform for the recruitment of other signaling
molecules still to be discovered. Because TNF-R1
contains an intracellular DD instead of a TIR domain,
other signaling molecules are recruited. However,
similar to the homotypic TIR-TIR interactions in the
recruitment of adaptor proteins to TLR/IL-1R, ho-
motypic DD-DD interactions mediate the recruit of
different adaptor proteins to the TNF-R1. Down-
stream signaling involves the activation of kinases and
ubiquitin ligases, of which some are receptor-specific
and others are not. IRAK-1 and IRAK-4 mediate
TLR/IL-1R signaling, and their counterparts in TNF-
R signaling are RIP1 and most likely RIP4 [105].
However, RIP1 seems to be a more universal player,
which can also take part in TLR signaling and many
other receptor specific signaling pathways to NF-kB
[106]. TLR/IL-1R aswell as TNF-R signaling does not
depend on the catalytic activity of the above-men-
tioned kinases, although they are functionally active.
The exact role of their catalytic activity still needs to
be identified, but a role in the fine-tuning of NF-kB
activation is most likely. Similar to the use of distinct
kinases, TLR/IL-1R and TNF-R signaling depends on
distinct members of the TRAF family, TRAF6 and
TRAF2/TRAF5, respectively. Originally thought to
be simple adaptors, TRAF molecules are now recog-
nized to function as ubiquitin ligases, leading to K63-
linked auto-poly-ubiquitination and the K63-linked
poly-ubiquitination of other signaling proteins, thus
creating novel docking sites for the binding of other
ubiquitin-binding proteins. Alternatively, K48-linked
poly-ubiquitination of signaling proteins results in
their proteasome mediated degradation. In this con-
text, both RIP1 and IRAK-1 are modified in both
ways, with K48-poly-ubiquitination leading to their
degradation and the ending of signaling. ForRIP1, this
negative regulatory mechanism has been attributed to
A20, whereas for IRAK-1 the identity of the E3-ligase
remains unclear, although Pellino proteins might be
good candidates. TLR/IL-1R and TNF-R signaling
downstream of RIP1 and IRAK-1 converges on
TAK1, which functions as an activating kinase for
IKKb. In addition to this phosphorylation-dependent
activation step, the IKK complex is also activated by
induced oligomerization, which is mediated by the
K63-poly-ubiquitin-dependent recruitment of the
IKK adaptor protein IKKg to K63-poly-ubiquitinated
RIP1 and IRAK-1 in the TNF-R and TLR/IL-1R
signaling pathway, respectively. It is clear that early
signaling of these receptors follows many common
themes but involving distinct signaling molecules. The
use of different molecules exerting similar functions
allows the cell to specifically regulate the effect of for
example TLR stimulation, leaving the effect of TNF-
R1 signaling intact. Several examples of negative
regulatorymolecules interferingwithNF-kB signaling
in a receptor-specific way are already known, such as
A20 [107], MyD88s [108, 109] and TAX1BP1 [110,
111].
Anti-TNF therapies (e.g. adalimumab, a fully human
monoclonal antibody; etanercept, a soluble receptor
construct; and infliximab, a chimeric monoclonal
antibody) have already found their way to the clinic
for the treatment of autoimmune diseases, such as
rheumatoid arthritis, Crohns disease and psoriasis.
Similarly, anti-IL-1 therapy (anakinra, a recombinant
form of a naturally occurring IL-1RI-binding mole-
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cule) has been approved to manage rheumatoid
arthritis patients but seems to be less effective than
anti-TNF therapy. Anti-TNF and anti-IL-1 therapies
are associated with an increased risk of infection as
well as other potentially serious side effects and are
therefore only used for patients that are refractory to
more conventional forms of treatment [112]. More
recently, also manipulating the activity of TLRs to
modulate immune responses for therapeutic purposes
has initiated intense activity in the pharmaceutical
industry. The focus of these activities has been largely
on the use of TLR agonists or antagonists in the areas
of infectious diseases, cancer, allergic diseases and
vaccine adjuvants [113]. Although initial clinical trials
for infectious diseases and cancer showed early
promise, subsequent longer-term trials have been
disappointing, and more research is required to find
strategies that balance efficacy with acceptable side-
effect profiles. In this context, inhibition of the NF-kB
signaling pathway to prevent the expression of pro-
inflammatory mediators or to sensitize tumor cells to
anti-cancer treatment has been proposed, and clinical
trials with several IKK inhibitors are ongoing. How-
ever, NF-kB inhibition at the level of IKK is a double-
edged sword. NF-kB signaling pathways initiated
from distinct receptors all converge at the level of
IKK, implying that IKK inhibitors block signaling in
response to multiple receptors that play crucial roles
in maintaining health and immune surveillance. It is
therefore likely that IKK inhibitors will also have
significant side-effects, particularly if they are used for
a long time. More promising would be inhibitors that
target the NF-kB pathway initiated by a specific
receptor whose deregulated activity is linked to a
certain disease, leaving NF-kB activation in response
to other receptors intact. An increased understanding
of the mechanisms that regulate NF-kB activation in
response to TNF-R, IL-1R and TLRs can therefore be
expected to open new avenues for therapeutic drug
development.
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